LAPC4

细胞系

LAPC4是在腫瘤學領域中常用的人類前列腺癌細胞系,最初是從一名男性前列腺癌患者淋巴結中轉移,並且將其異種移植到患有嚴重複合型免疫缺乏症小鼠中,然後收集及鋪設在培養基中,則可以作為永生化的前列腺癌細胞系進行繁殖[1][2][3]

LAPC4細胞的相襯顯微照片

特徵

LAPC4細胞的倍增時間約為72小時。LAPC4是具有雄激素受體前列腺特異抗原高度表達的低粘附性上皮細胞系,其與對雄激素受體呈陽性反應的前列腺癌細胞系LNCaP和VCaP等常用細胞系不同,具有較高的Keratin 5英語Keratin 5(即基礎標記物)及腔標記物Keratin 8英語Keratin 8Keratin 18英語Keratin 18的表達[4]

參考資料

  1. ^ Klein, KA; Reiter, RE; Redula, J; Moradi, H; Zhu, XL; Brothman, AR; Lamb, DJ; Marcelli, M; Belldegrun, A; Witte, ON; Sawyers, CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.. Nature medicine. 1997-04, 3 (4): 402–8 [2020-01-03]. PMID 9095173. doi:10.1038/nm0497-402. (原始內容存檔於2020-01-03). 
  2. ^ Russell, Pamela J.; Kingsley, Elizabeth A. Chapter 2: Human Prostate Cancer Cell Lines (PDF). Russell, Pamela J.; Jackson, Paul; Kingsley, Elizabeth A. (編). Prostate cancer methods and protocols. Totowa, N.J.: Humana Press. 2003: 21–39 [2020-01-03]. ISBN 978-1-59259-372-9. (原始內容存檔 (PDF)於2020-07-10). 
  3. ^ Garcia, RR; Masoodi, KZ; Pascal, LE; Nelson, JB; Wang, Z. Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.. American journal of clinical and experimental urology. 2014, 2 (1): 82–91 [2020-01-03]. PMID 25374909. (原始內容存檔於2020-01-03). 
  4. ^ van Bokhoven, A; Varella-Garcia, M; Korch, C; Johannes, WU; Smith, EE; Miller, HL; Nordeen, SK; Miller, GJ; Lucia, MS. Molecular characterization of human prostate carcinoma cell lines.. The Prostate. 2003-11-01, 57 (3): 205–25 [2020-01-03]. PMID 14518029. doi:10.1002/pros.10290. (原始內容存檔於2020-01-03). 

外部連結